SARS-CoV-2 NP ORF Mammalian Expression
To Order Contact us: stephen@expresspharmapulse.com
SARS CoV-2 PCR kit |
|||
PCR-H731-96R | Bioingentech | 96T | EUR 1113 |
Anti-SARS-CoV-2 Antibody |
|||
A2061-50 | Biovision | 50 µg | EUR 480 |
SARS-CoV-2 Spike Peptide |
|||
9083P | ProSci | 0.05 mg | EUR 196.25 |
Description: (NT) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike Peptide |
|||
9087P | ProSci | 0.05 mg | EUR 196.25 |
Description: (CT) SARS-CoV-2 Spike RBD peptide |
SARS-CoV-2 Spike Peptide |
|||
9091P | ProSci | 0.05 mg | EUR 196.25 |
Description: (IN) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike Peptide |
|||
9095P | ProSci | 0.05 mg | EUR 196.25 |
Description: (IN) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Nucleocapsid Peptide |
|||
9099P | ProSci | 0.05 mg | EUR 196.25 |
Description: (IN) SARS-CoV-2 Nucleocapsid peptide |
SARS-CoV-2 Nucleocapsid Peptide |
|||
9103P | ProSci | 0.05 mg | EUR 196.25 |
Description: (CT) SARS-CoV-2 Nucleocapsid peptide |
SARS-CoV-2 Antigen ELISA Kit |
|||
DEIA2020 | Creative Diagnostics | 96 tests | EUR 905 |
Description: SARS-CoV-2 Antigen ELISA Kit intended use is for quantitative detection of the recombinant SARS-COV-2 nucleoprotein antigen in human serum. The use of this kit for natural samples need to be validated by the end user due to the complexity of natural targets and unpredictable interference. |
SARS CoV-2 RT PCR kit |
|||
RTq-H731-100R | Bioingentech | 100T | EUR 1311 |
SARS CoV-2 RT PCR kit |
|||
RTq-H731-150R | Bioingentech | 150T | EUR 1787 |
SARS CoV-2 RT PCR kit |
|||
RTq-H731-50R | Bioingentech | 50T | EUR 963 |
SARS-CoV-2 IgG ELISA Kit |
|||
E4901-100 | Biovision | 100 assays | EUR 753 |
Recombinant Coronavirus Nucleoprotein (SARS-CoV-2) |
|||
P1523-10 | Biovision | 10 µg | EUR 156 |
Recombinant Coronavirus Nucleoprotein (SARS-CoV-2) |
|||
P1523-50 | Biovision | 50 µg | EUR 551 |
SARS-CoV-2 Spike S2 Peptide |
|||
9119P | ProSci | 0.05 mg | EUR 196.25 |
Description: (IN) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike S2 Peptide |
|||
9123P | ProSci | 0.05 mg | EUR 196.25 |
Description: (CT) SARS-CoV-2 Spike peptide |
Anti-CoV-2 & SARS-CoV S1 Antibody (Clone# CR3022) |
|||
A2103-200 | Biovision | 200 µg | EUR 480 |
SARS CoV E Protein |
|||
abx060650-1mg | Abbexa | 1 mg | EUR 1692 |
SARS CoV Nucleocapsid Protein |
|||
abx060652-1mg | Abbexa | 1 mg | EUR 1873 |
SARS-CoV Nucleocapsid Protein |
|||
abx060653-1mg | Abbexa | 1 mg | EUR 1692 |
SARS-CoV Nucleocapsid Protein |
|||
abx060654-1mg | Abbexa | 1 mg | EUR 1692 |
SARS-CoV Spike Protein |
|||
abx060655-1mg | Abbexa | 1 mg | EUR 1692 |
SARS-CoV Spike Antibody |
|||
3219-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3219-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3221-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3221-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3223-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3223-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3225-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3225-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Matrix Antibody |
|||
3527-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
|||
3527-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
|||
3529-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
|||
3529-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Envelope Antibody |
|||
3533-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
SARS-CoV Envelope Antibody |
|||
3533-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
anti-MERS-CoV NP (2C11) |
|||
AR12-MA0010 | Abfrontier | 100 ul | EUR 334 |
Description: Mouse monoclonal to MERS-CoV NP |
anti-MERS-Cov NP (2D2) |
|||
AR12-MA0011 | Abfrontier | 100 ul | EUR 334 |
Description: Mouse monoclonal to MERS-CoV NP |
SARS CoV-2 One-Step PCR kit |
|||
Oneq-H731-100R | Bioingentech | 100T | EUR 1610 |
SARS CoV-2 One-Step PCR kit |
|||
Oneq-H731-150R | Bioingentech | 150T | EUR 2205 |
SARS CoV-2 One-Step PCR kit |
|||
Oneq-H731-50R | Bioingentech | 50T | EUR 1175 |
Anti-SARS-CoV-2 Antibody (Clone# 6F10) |
|||
A2060-50 | Biovision | 50 µg | EUR 480 |
Anti-SARS-CoV-2 Spike S1 Antibody |
|||
A3000-50 | Biovision | 50 µg | EUR 419 |
Coronavirus (SARS-CoV-2) PCR Detection Kit |
|||
K1460 | Biovision | 100 Rxns | EUR 570 |
Description: Kit for detection of SARS-CoV-2 in respiratory specimens using Real-Time (RT-PCR). |
Coronavirus (SARS-CoV-2) PCR Detection Kit |
|||
K1460-100 | Biovision | 100 Rxns | EUR 551 |
Recombinant SARS-CoV-2 Nucleoprotein (1-430) |
|||
P1537-10 | Biovision | 10 µg | EUR 156 |
Recombinant SARS-CoV-2 Nucleoprotein (1-430) |
|||
P1537-50 | Biovision | 50 µg | EUR 530 |
Recombinant SARS-CoV-2 Nucleoprotein (1-430) |
|||
P1539-10 | Biovision | 10 µg | EUR 156 |
Recombinant SARS-CoV-2 Nucleoprotein (1-430) |
|||
P1539-50 | Biovision | 50 µg | EUR 530 |
Recombinant SARS-CoV-2 3C-like Proteinase |
|||
P1550-10 | Biovision | 10 μg | EUR 156 |
Recombinant SARS-CoV-2 3C-like Proteinase |
|||
P1550-50 | Biovision | 50 μg | EUR 551 |
Recombinant SARS-CoV-2 Papain-like Protease |
|||
P1551-10 | Biovision | 10 μg | EUR 156 |
Recombinant SARS-CoV-2 Papain-like Protease |
|||
P1551-50 | Biovision | 50 μg | EUR 551 |
SARS-CoV-2 Antigen Rapid Test Kit |
|||
CoV2Ag-1 | UnScience | 1T | EUR 8 |
Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again. |
SARS-CoV-2 Antigen Rapid Test Kit |
|||
CoV2Ag-25 | UnScience | 25T/kit | EUR 35 |
Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection. |
SARS-CoV-2 Rapid Antigen Test Nasal |
|||
9901-NCOV-03G | Roche Diagnostics | 25 Tests/Kit | EUR 94 |
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke |
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
3525-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
3525-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Envelope Antibody |
|||
3531-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3). |
SARS-CoV-2 (COVID-19) Envelope Antibody |
|||
3531-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3). |
SARS-CoV-2 (COVID-19) NSP7 Peptide |
|||
9155P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) NSP7 Peptide |
SARS-CoV-2 (COVID-19) Membrane Peptide |
|||
9157P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) Membrane Peptide |
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
9159P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
9161P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
9163P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
SARS-CoV-2 (COVID-19) Membrane Peptide |
|||
9165P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) Membrane Peptide |
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
9167P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
SARS-CoV-2 (COVID-19) Envelope Peptide |
|||
9169P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) Envelope Peptide |
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
9171P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
9173P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
SARS-CoV-2 (COVID-19) NSP4 Peptide |
|||
9175P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) NSP4 Peptide |
SARS-CoV-2 (COVID-19) NSP6 Peptide |
|||
9177P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) NSP6 Peptide |
SARS-CoV-2 (COVID-19) NSP10 Peptide |
|||
9179P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) NSP10 Peptide |
SARS-CoV-2 (COVID-19) ORF6 Peptide |
|||
9189P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF6 Peptide |
SARS-CoV-2 (COVID-19) ORF9b Peptide |
|||
9191P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF9b Peptide |
SARS-CoV-2 (COVID-19) ORF3a Peptide |
|||
9275P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF3a Peptide |
SARS-CoV-2 (COVID-19) ORF3b Peptide |
|||
9277P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide |
SARS-CoV-2 (COVID-19) ORF3b Peptide |
|||
9279P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide |
SARS-CoV-2 (COVID-19) ORF3b Peptide |
|||
9281P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide |
SARS-CoV-2 (COVID-19) ORF7a Peptide |
|||
9283P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF7a Peptide |
SARS-CoV-2 (COVID-19) ORF7a Peptide |
|||
9285P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF7a Peptide |
SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
9287P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide |
SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
9289P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide |
SARS-CoV-2 (COVID-19) ORF9c Peptide |
|||
9291P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF9c Peptide |
SARS-CoV-2 (COVID-19) ORF10 Peptide |
|||
9293P | ProSci | 0.05 mg | EUR 196.25 |
Description: SARS-CoV-2 (COVID-19) ORF10 Peptide |
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody |
|||
9099-002mg | ProSci | 0.02 mg | EUR 191.42 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody |
|||
9099-01mg | ProSci | 0.1 mg | EUR 495.22 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody |
|||
9103-002mg | ProSci | 0.02 mg | EUR 191.42 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody |
|||
9103-01mg | ProSci | 0.1 mg | EUR 495.22 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
|||
9155-002mg | ProSci | 0.02 mg | EUR 191.42 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
|||
9155-01mg | ProSci | 0.1 mg | EUR 495.22 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |